Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Nanologica AB ( (SE:NICA) ) has issued an update.
Nanologica AB has entered the Chinese insulin market with a SEK 2 million order for its silica-based purification media, NLAB Saga®, from an insulin manufacturer. This marks the first evaluation of NLAB Saga® for insulin manufacturing in China, highlighting the company’s expanding market reach and potential to lower manufacturing costs for clients, thereby strengthening its industry position.
The most recent analyst rating on (SE:NICA) stock is a Hold with a SEK1.50 price target. To see the full list of analyst forecasts on Nanologica AB stock, see the SE:NICA Stock Forecast page.
More about Nanologica AB
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. The company specializes in products for the purification of peptide drugs, such as insulin and GLP-1 analogues, which help increase productivity and reduce costs for pharmaceutical manufacturers. Operating in a global niche market, Nanologica aims to increase access to cost-effective drugs, contributing to life-saving treatments worldwide. The company is headquartered in Södertälje and its shares are listed on Nasdaq Stockholm Main Market.
Average Trading Volume: 112,383
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK103.4M
For an in-depth examination of NICA stock, go to TipRanks’ Overview page.